Top 10 Psychedelic Papers of 2024

Using dense longitudinal fMRI mapping, a single high dose of psilocybin massively desynchronised cortical and subcortical communication between brain networks—dissolving within-network correlations and between-network anticorrelations—far more than methylphenidate and with the strongest effect in the default mode network. These acute changes tracked subjective experience, were attenuated by a perceptual task, and included a persistent reduction in anterior hippocampus–DMN coupling lasting weeks that may underlie psilocybin’s proplasticity and therapeutic effects.

Prospective docking of large libraries against unrefined AlphaFold2 (AF2) models of the σ2 and 5‑HT2A receptors yielded hit rates and affinities similar to those from experimental structures, and cryo‑EM of a potent 5‑HT2A ligand showed residue accommodations resembling the AF2 prediction. This demonstrates that AF2 models can sample alternative low‑energy conformations relevant for ligand discovery, extending the utility of structure‑based drug design. It adds a concrete angle on the most notable psychedelic research published in 2024, helping readers understand the topic through evidence rather than broad claims alone.

The review and meta‑analysis of 214 studies found that high‑dose classic psychedelics were generally well tolerated in clinical/research settings. Common non‑serious adverse events (headache, anxiety, nausea, fatigue, dizziness) had similar prevalences for psilocybin and LSD, but substantial heterogeneity and limited systematic adverse‑event monitoring across studies highlight the need for improved pharmacovigilance. That makes it useful as a map of the most notable psychedelic research published in 2024: it shows where evidence clusters, where the field is thin, and which claims need more cautious reading.

This opinion piece (2023) challenges the traditional conceptualization of psychedelic-assisted psychotherapy (PAP/PAT), emphasizing that the therapeutic effects of psychedelics should not be solely attributed to the substance itself but also to the importance of psychotherapy. The authors argue against reducing the role of psychotherapy to mere psychological support for safety, advocating for a more integrated approach to understanding and studying the therapeutic potential of psychedelics in treating psychiatric disorders. It adds a concrete angle on the most notable psychedelic research published in 2024, helping readers understand the topic through evidence rather than broad claims alone.

In an open‑label, non‑randomised 12‑week trial of people with treatment‑resistant bipolar II depression, a single 25 mg dose of synthetic psilocybin plus psychotherapy produced large, rapid and sustained reductions in depressive symptoms without significant increases in mania or suicidality. These preliminary results suggest psilocybin may be an effective and safe acute treatment for bipolar II depression and merit confirmation in larger randomised controlled trials. It adds a concrete angle on the most notable psychedelic research published in 2024, helping readers understand the topic through evidence rather than broad claims alone.

The open-label waitlist trial assessed the feasibility of psilocybin-assisted psychotherapy (PAP/PAT) in a complex population with treatment-resistant depression (TRD), including major depressive and bipolar II disorders, baseline suicidality, and significant comorbidity. Participants received one, two, or three sessions of PAP with psilocybin, accompanied by preparation and integration psychotherapy sessions. Immediate treatment showed greater reductions in depression severity compared to the waitlist period. Adverse events were transient, and the study demonstrated feasibility, preliminary antidepressant efficacy, safety, and tolerability in this population.

The molecular study examines the underpinnings of 5-MeO-DMT pharmacology and its therapeutic potential through cryogenic electron microscopy structures of 5-HT1A, medicinal chemistry, receptor mutagenesis, and mouse behaviour. The research characterizes molecular determinants of 5-HT1A signalling potency, efficacy, and selectivity, contrasting the structural interactions and pharmacology of 5-MeO-DMT with LSD and clinically used 5-HT1A agonists. Its main value is mechanistic: it helps connect subjective or clinical effects to biology instead of treating the drug experience as a black box.

In a double-blind randomised trial comparing escitalopram and COMP360 psilocybin for major depressive disorder, pre-treatment expectancy predicted response to escitalopram but not to psilocybin, whereas baseline trait suggestibility was associated with response to psilocybin only. These findings suggest psychedelic therapy may be less vulnerable to expectancy biases but could be particularly effective in highly suggestible individuals. For readers, the value is not just the result but the study design: it shows how the most notable psychedelic research published in 2024 performs when tested under more structured clinical conditions.

Though only observational (measuring before and after, not doing a randomized clinical trial), The paper provides a positive signal for both the safety and efficacy of ibogaine therapy. Its main value is mechanistic: it helps connect subjective or clinical effects to biology instead of treating the drug experience as a black box. Together with the other papers from the year, it shows which parts of psychedelic science were becoming more rigorous, more contested, or more clinically relevant.

In a randomised, waiting‑list‑controlled psilocybin‑assisted therapy trial for major depressive disorder, therapeutic alliance strengthened over time and higher alliance ratings before and shortly after dosing predicted stronger acute mystical and psychological‑insight experiences and greater reductions in depressive symptoms up to 12 months. These results highlight the therapeutic relationship as an important predictor of both acute psychedelic experiences and long‑term clinical outcomes. For readers, the value is not just the result but the study design: it shows how the most notable psychedelic research published in 2024 performs when tested under more structured clinical conditions.